Release date: 2016-10-10
According to the latest study published at the American Society for Radiation Oncology (ASTRO) 2016, quality of life (QoL) outcomes and traditional RT for hypofractionated RT in patients with low-risk prostate cancer The treatment is similar, but it only takes up one-third of the treatment time.
Â
Dr. Deborah Bruner, the first author of the study, noted that large-segment radiotherapy has previously been found to have similar efficacy in terms of progression-free survival compared to traditional methods. Despite this, large-segment radiotherapy remains at the research stage. Dr. Bruner believes that the conclusions of this latest study should be considered in the revision of radiotherapy guidelines for patients with low-risk prostate cancer.
Â
The results of this latest study are critical because researchers have been concerned about the side effects of high-intensity, high-resolution radiotherapy. At the ASTRO Annual Meeting last year, the NRG ONCOLOGY/RTOG 0415 trial conducted extensive research on the relevant safety conclusions. According to the results of the clinician's report, the grade 2 gastrointestinal and genitourinary adverse reactions in the large-segment radiotherapy group. slightly increased.
Â
The conclusion of the latest study is the treatment outcome reported by the patient. QoL and toxicity results are important in non-inferiority trials as this is likely to be the final difference in the treatment group. In the study, the researchers randomized patients to two treatment groups: the large-segment radiotherapy group (70 Gy, 5.6 weeks, 28 times) and the conventional radiotherapy group (73.8 Gy, 8.2 weeks, 41 times).
Â
In the study, a total of 962 patients were reported for QoL in the gut, urinary, hormonal, and sexual life using the Expanded Prostate Index Composite questionnaire. The median age of the patients was 67 years. The researchers collected feedback from participants as baseline data and collected feedback for 6 months after treatment and 1 year after treatment, comparing the two groups of data.
Â
There were no statistical differences in QoL baseline data between the 2 groups of patients. There were no significant differences in follow-up data at 6 months.
Â
However, at the 12th month, patients receiving large-segment radiotherapy had a 3.6 and 1.8 reduction in questionnaire scores compared with patients receiving conventional radiotherapy (P = 0.0037). However, the patient did not feel a significant difference in the difference.
Â
Sexual function decreased significantly in both groups: the traditional RT group decreased by 15 points, and the large-segment radiotherapy group decreased by 11 points. The difference was not statistically significant.
There was almost no decrease in the urinary system score: the traditional RT group decreased by 0 , and the large-segment radiotherapy group decreased by 2 points. The difference was not statistically significant.
Hormone scores did not change compared to baseline data.
Â
“Now, we have ample evidence that patients with low-risk prostate cancer can be treated with large-segment radiotherapy and are fairly safe.†Dr. Bruner concluded that large-segment radiotherapy allows patients to receive treatment similar to traditional RT in a shorter treatment period. The effect, but less cost, is easier to treat.
Â
Dr. Colleen Lawton of the University of Wisconsin Medical School agrees with this view: "Shorter treatments mean lower cost of care, and more patients are able to afford treatment and receive cancer radiotherapy."
Source: Medical Network
Roxadustat Intermediate
Roxadustat Intermediate,Fg-4592 Intermediate,Cas 1455091-10-7,Cas 1455091-10-7 Roxadustat Intermediate
Shijiazhuang Dingmin pharmaceutical Sciences Co.,Ltd , https://www.dingminpharma.com